SMT201400196B - 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato - Google Patents

6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato

Info

Publication number
SMT201400196B
SMT201400196B SM201400196T SM201400196T SMT201400196B SM T201400196 B SMT201400196 B SM T201400196B SM 201400196 T SM201400196 T SM 201400196T SM 201400196 T SM201400196 T SM 201400196T SM T201400196 B SMT201400196 B SM T201400196B
Authority
SM
San Marino
Prior art keywords
methylbutyl
purine
piperidinyl
maleate
dihydro
Prior art date
Application number
SM201400196T
Other languages
English (en)
Italian (it)
Inventor
Robert Hermann Gibbon
Amanda Lucas
Stephen Andrew Hermitage
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SMT201400196B publication Critical patent/SMT201400196B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
SM201400196T 2010-02-10 2014-12-30 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato SMT201400196B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate

Publications (1)

Publication Number Publication Date
SMT201400196B true SMT201400196B (it) 2015-01-15

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400196T SMT201400196B (it) 2010-02-10 2014-12-30 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato

Country Status (23)

Country Link
US (1) US8703754B2 (OSRAM)
EP (1) EP2534149B1 (OSRAM)
JP (1) JP5922587B2 (OSRAM)
KR (1) KR101773541B1 (OSRAM)
CN (1) CN102753553B (OSRAM)
AU (1) AU2011214468B2 (OSRAM)
BR (1) BR112012018904A2 (OSRAM)
CA (1) CA2786973C (OSRAM)
DK (1) DK2534149T3 (OSRAM)
EA (1) EA021048B1 (OSRAM)
ES (1) ES2525826T3 (OSRAM)
HR (1) HRP20141258T1 (OSRAM)
IL (1) IL220845A (OSRAM)
ME (1) ME01926B (OSRAM)
MX (1) MX2012009316A (OSRAM)
PL (1) PL2534149T3 (OSRAM)
PT (1) PT2534149E (OSRAM)
RS (1) RS53745B1 (OSRAM)
SG (1) SG182471A1 (OSRAM)
SI (1) SI2534149T1 (OSRAM)
SM (1) SMT201400196B (OSRAM)
WO (1) WO2011098452A1 (OSRAM)
ZA (1) ZA201205995B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
IN2012DN00720A (OSRAM) 2009-07-06 2015-06-19 Ontorii Inc
EA020488B1 (ru) 2009-10-22 2014-11-28 Джилид Сайэнс, Инк. Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
MX347361B (es) 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
WO2013014052A1 (en) * 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
EP2872147B1 (en) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Method for making chiral oligonucleotides
EP2872485B1 (en) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetric auxiliary group
AU2013287630B2 (en) * 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
BR112015003259A2 (pt) 2012-08-24 2017-08-08 Glaxosmithkline Llc composto, composição farmacêutica, e, composição de vacina.
WO2014081643A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
PT2922549T (pt) 2012-11-20 2017-09-01 Glaxosmithkline Llc Novos compostos
WO2014081644A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
JP7109188B2 (ja) * 2014-08-29 2022-07-29 コリウム， インコーポレイテッド 活性剤の送達のための微細構造アレイ
CA2967248A1 (en) * 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
WO2020110584A1 (ja) * 2018-11-28 2020-06-04 株式会社島津製作所 アゾ化合物の分析方法
KR20250106231A (ko) 2023-12-29 2025-07-09 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1065213A3 (en) 1999-07-02 2003-11-05 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
TR200103147T1 (tr) 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
CZ20032532A3 (en) 2001-03-19 2004-03-17 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro 5.5 undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP1411928A1 (en) 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2481502A1 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
MXPA05004435A (es) 2002-10-24 2005-07-26 Glaxo Group Ltd Derivados de 1-acil-pirrolidina para el tratamiento de infecciones virales.
ATE402176T1 (de) 2002-12-13 2008-08-15 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
EP1581530A1 (en) 2002-12-13 2005-10-05 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
BR0317230A (pt) 2002-12-13 2005-10-25 Smithkline Beecham Corp Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto
US7452992B2 (en) 2002-12-13 2008-11-18 Smithkline Beecham Corporation Heterocyclic compounds as CCR5 antagonists
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
JP4641526B2 (ja) 2003-11-03 2011-03-02 グラクソ グループ リミテッド 流体分配デバイス
SG184700A1 (en) 2004-02-20 2012-10-30 Boehringer Ingelheim Int Viral polymerase inhibitors
JP2007534735A (ja) 2004-04-28 2007-11-29 アロウ セラピューティクス リミテッド 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2577525C (en) 2004-08-18 2010-03-30 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2006026394A2 (en) 2004-08-27 2006-03-09 3M Innovative Properties Company Method of eliciting an immune response against hiv
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
WO2006122011A2 (en) 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JPWO2007034881A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
US20100120799A1 (en) 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
EP2132209B8 (en) * 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Also Published As

Publication number Publication date
JP5922587B2 (ja) 2016-05-24
US8703754B2 (en) 2014-04-22
CA2786973A1 (en) 2011-08-18
CN102753553B (zh) 2016-03-30
CA2786973C (en) 2018-04-10
AU2011214468B2 (en) 2015-05-28
MX2012009316A (es) 2012-09-12
EP2534149A1 (en) 2012-12-19
ZA201205995B (en) 2014-01-29
JP2013519645A (ja) 2013-05-30
WO2011098452A1 (en) 2011-08-18
EP2534149B1 (en) 2014-10-15
CN102753553A (zh) 2012-10-24
AU2011214468A1 (en) 2012-08-09
RS53745B1 (sr) 2015-06-30
US20120308609A1 (en) 2012-12-06
KR101773541B1 (ko) 2017-08-31
EA021048B1 (ru) 2015-03-31
PL2534149T3 (pl) 2015-03-31
DK2534149T3 (da) 2015-01-05
PT2534149E (pt) 2014-12-23
HRP20141258T1 (hr) 2015-02-27
SG182471A1 (en) 2012-08-30
ES2525826T3 (es) 2014-12-30
EA201290631A1 (ru) 2013-03-29
KR20120135408A (ko) 2012-12-13
BR112012018904A2 (pt) 2020-09-01
IL220845A (en) 2016-08-31
ME01926B (me) 2015-05-20
SI2534149T1 (sl) 2015-02-27

Similar Documents

Publication Publication Date Title
SMT201400196B (it) 6-Ammino-2-[[[(1S)-1-metilbutil]ossi]]-9-[5-(1-piperidinil)pentil]-7,9-diidro-8H-purin-8-one maleato
IL266285B (en) Methods for the production of thiano [d – 3,2] pyrimidine compounds
EP2624698A4 (en) Furo [3,2-D] PYRIMIDINE COMPOUNDS
AP2939A (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors
AP2811A (en) Sulfonamide derivatives
SG11201402197UA (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
BRPI1014459A2 (pt) derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"
ZA201109340B (en) Pyrimidinones as pi3k inhibitors
SI2473053T1 (sl) Substiturani derivati ksantina
IL233282A0 (en) Manufacturing process for pyrimidine history
ZA201209029B (en) Novel pyrimidine derivatives
IL232304A0 (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
ZA201009272B (en) Substituted alkyl pyrimidin-4-one derivatives
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
IL219371A0 (en) Ethynyl derivatives
IL232717B (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
EP2616477A4 (en) 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS
IL212942A0 (en) Rifamycin derivatives
IL219603A0 (en) Imidazopyridine derivatives
EP2516420B8 (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
IL219635A0 (en) Heterocyclic sulfonamide derivatives
AU2011355362B2 (en) 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives
HK1187783A (en) Furo[3,2-d]pyrimidine compounds
HK1175070A (en) Risperidone immunoassay
AU2012244368A1 (en) Automatic routing using search results